97 related articles for article (PubMed ID: 15237462)
1. Adjuvant treatment of breast cancer with exemestane.
Vakaet LA; De Neve W
N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15237462
[No Abstract] [Full Text] [Related]
2. Adjuvant treatment of breast cancer with exemestane.
Kunkler IH
N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15229316
[No Abstract] [Full Text] [Related]
3. Adjuvant treatment of breast cancer with exemestane.
Tanvetyanon T
N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15237463
[No Abstract] [Full Text] [Related]
4. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
Hutchinson L
Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
[No Abstract] [Full Text] [Related]
5. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
[TBL] [Abstract][Full Text] [Related]
6. Longer time to tumor progression with exemestane vs tamoxifen in advanced breast cancer.
Oncology (Williston Park); 2000 Sep; 14(9):1291, 1294. PubMed ID: 11033826
[No Abstract] [Full Text] [Related]
7. New stars in the sky of treatment for early breast cancer.
Piccart-Gebhart MJ
N Engl J Med; 2004 Mar; 350(11):1140-2. PubMed ID: 15014188
[No Abstract] [Full Text] [Related]
8. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
9. Exemestane or tamoxifen?
Atkins CD
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499597
[No Abstract] [Full Text] [Related]
10. Exemestane or tamoxifen?
Ueda M; Toji E; Noda S
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
[No Abstract] [Full Text] [Related]
11. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Clemons M; Coleman RE; Verma S
Cancer Treat Rev; 2004 Jun; 30(4):325-32. PubMed ID: 15145507
[TBL] [Abstract][Full Text] [Related]
13. Time to TEAM: exemestane, or tamoxifen then exemestane?
Coombes RC; Kilburn LS
Lancet; 2011 Jan; 377(9762):280-1. PubMed ID: 21256370
[No Abstract] [Full Text] [Related]
14. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
15. Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Aapro M
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S1. PubMed ID: 18337639
[No Abstract] [Full Text] [Related]
16. Switching to aromatase inhibitors in early breast cancer.
Boccardo F; Rubagotti A
Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
[No Abstract] [Full Text] [Related]
17. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
Prescrire Int; 2005 Jun; 14(77):108-10. PubMed ID: 15984106
[TBL] [Abstract][Full Text] [Related]
19. The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Herold CI; Blackwell KL
Breast; 2008 Jan; 17 Suppl 1():S15-24. PubMed ID: 18279763
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Pritchard KI
J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
